Kamada Ltd. (NASDAQ:KMDA) shares reached a new 52-week high on Tuesday . The company traded as high as $5.34 and last traded at $5.04, with a volume of 307,314 shares trading hands. The stock had previously closed at $4.53.

KMDA has been the topic of a number of analyst reports. Zacks Investment Research upgraded shares of Kamada from a “hold” rating to a “buy” rating and set a $4.50 target price on the stock in a research note on Thursday, May 12th. Jefferies Group reiterated a “buy” rating and issued a $7.00 price target on shares of Kamada in a research note on Wednesday. Finally, TheStreet cut shares of Kamada from a “hold” rating to a “sell” rating in a research note on Thursday, June 9th.

The company has a 50 day moving average of $4.15 and a 200 day moving average of $3.89. The company’s market cap is $175.53 million.

Kamada (NASDAQ:KMDA) last issued its quarterly earnings results on Tuesday, August 2nd. The company reported ($0.04) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.04). The company had revenue of $19.10 million for the quarter, compared to analyst estimates of $18.50 million. On average, equities analysts forecast that Kamada Ltd. will post ($0.11) earnings per share for the current year.

Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.